Sequence: Stearyl-HHHCRRRRRC
siRNA (NC; fluorescently labeled)
| Experiment Id | EXP001162 |
|---|---|
| Paper | A biodegradable stearylated peptide with internal disulfide bonds for efficient delivery of siRNA in |
| Peptide | SHRss2 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | N/P=10 (uptake studies); inhibitor study uses 25 nM Cy3-siRNA; uptake flow cytometry uses 75 nM |
| Rna Concentration | 75 nM Cy3-siRNA (flow cytometry/confocal uptake); 25 nM (inhibitor pathway assay) |
| Mixing Ratio | N/P=10 |
| Formulation Format | Electrostatic polyplex (SHRss2/Cy3-siRNA) |
| Formulation Components | SHRss2 + Cy3-siRNA |
| Size Nm | 163.00 |
| Zeta Mv | 24.60 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | Luc-Hela cells |
| Animal Model | |
| Administration Route | |
| Output Type | Cellular uptake / intracellular localization (flow cytometry, confocal) |
| Output Value | High uptake (~near 100% Cy3-positive cells for SHRss variants); cytosolic distribution observed for SHRss2 |
| Output Units | |
| Output Notes | Major uptake pathways: clathrin- and caveolae-mediated endocytosis (inhibitor studies). Confocal at 3 h and 24 h showed Cy3-siRNA largely in cytoplasm for SHRss2. |
| Toxicity Notes | |
| Curation Notes |